Salt, aldosterone, and insulin resistance: Impact on the cardiovascular system

Nature Reviews Cardiology

Volumn 7, Issue 10, 2010, Pages 577-584

  Lastra, Guido ^a   Dhuper, Sonal ^a   Johnson, Megan S ^a   Sowers, James R ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID RECEPTOR; REACTIVE OXYGEN METABOLITE;

ADRENERGIC SYSTEM; ATHEROSCLEROSIS; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; GLUCOSE HOMEOSTASIS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SIGNAL TRANSDUCTION; SODIUM RESTRICTION;

ALDOSTERONE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MINERALOCORTICOIDS; OBESITY; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SIGNAL TRANSDUCTION; SODIUM, DIETARY; SYMPATHETIC NERVOUS SYSTEM;

EID: 77957311044     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.123     Document Type: Review

References (76)

1. Lastra, G., Manrique, C. M. & Sowers, J. R. Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv. Chronic Kidney Dis. 13, 365-373 (2006). (Pubitemid 44512240)
2. Lastra-Lastra, G., Sowers, J. R., Restrepo-Erazo, K., Manrique-Acevedo, C. & Lastra-González, G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin. Endocrinol. (Oxf.) 71, 1-6 (2009).
3. Strazzullo, P., Galletti, F. & Barba, G. Altered renal handling of sodium in human hypertension: short review of the evidence. Hypertension 41, 1000-1005 (2003). (Pubitemid 36548593)
4. De Wardener, H. E. & MacGregor, G. A. The natriuretic hormone and essential hypertension. Lancet 1, 1450-1454 (1982).
5. Houston, M. C. Sodium and hypertension. A review. Arch. Intern. Med. 146, 179-185 (1986).
6. Orlov, S. N. & Mongin, A. A. Salt-sensing mechanisms in blood pressure regulation and hypertension. Am. J. Physiol. Heart Circ. Physiol. 293, H2039-H2053 (2007). (Pubitemid 47605848)
7. Grim, C. E. et al. Racial differences in blood pressure in Evans County, Georgia: relationship to sodium and potassium intake and plasma renin activity. J. Chron. Dis. 33, 155-162 (1980).
8. Sacks, F. M. et al. Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH): A multicenter controlled-feeding study of dietary patterns to lower blood pressure. Ann. Epidemiol. 5, 108-118 (1995).
9. Sacks, F. M. et al. for the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N. Engl. J. Med. 344, 3-10 (2001). (Pubitemid 32064838)
10. Weinberger, M. H., Miller, J. Z., Luft, F C., Grim, C. E. & Fineberg, N. S. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 8, 127-134 (1996).
11. Weinberger, M. H. Salt sensitivity of blood pressure in humans. Hypertension 27, 481-490 (1996). (Pubitemid 26084617)
12. Franco, V. & Oparil, S. Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival. J. Am. Coll. Nutr. 25 (Suppl. 3), 247S-255S (2006). (Pubitemid 46931004)
13. Skrabal, F., Hamberger, L. & Ledochowski, M. Inherited salt sensitivity in normotensive humans as a cause of essential hypertension: a new concept. J. Cardiovasc. Pharmacol. 6 (Suppl. 1), S215-S223 (1984). (Pubitemid 14123992)
14. Weinberger, M. H., Fineberg, N. S., Fineberg, E. & Weinberger, M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 27, 429-432 (2001). (Pubitemid 32199006)
15. Rocchini, A. P. et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N. Engl. J. Med. 321, 580-585 (1989). (Pubitemid 19212870)
16. Zavaroni, I. et al. Association between salt sensitivity and insulin concentrations in patients with hypertension. Am. J. Hypertens. 8, 855-858 (1995).
17. Sharma, A. M., Ruland, K., Spies, K. P. & Distler, A. Salt sensitivity in young normotensive subjects is associated with a hyperinsulinemic response to oral glucose. J. Hypertens. 9, 329-335 (1991).
18. Galletti, F. et al. NaCI sensitivity of essential hypertensive patients is related to insulin resistance. J. Hypertens. 15, 1485-1491 (1997). (Pubitemid 28039578)
19. Melander, O., Groop, L. & Hulthén, U. L. Effect of salt on insulin sensitivity differs according to gender and degree of salt sensitivity. Hypertension 35, 827-831 (2000). (Pubitemid 30165333)
20. Agarwal, M. K., Mirshahi, F., Mirshahi, M. & Rostene, W. Immunochemical detection of the mineralocorticoid receptor in rat brain. Neuroendocrinology 5, 575-580 (1993). (Pubitemid 23343941)
21. Geerling, J. C., Kawata, M. & Loewy, A. D. Aldosterone-sensitive neurons in the rat central nervous system. J. Comp. Neurol. 494, 515-527 (2006). (Pubitemid 41790999)
22. Cornell, J. M. & Davies, E. The new biology of aldosterone. J. Endocrinol. 186, 1-20 (2005). (Pubitemid 41015660)
23. Gomez-Sanchez, E. P. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology 118, 819-823 (1986). (Pubitemid 16162807)
24. DiBona, G. F & Sawin, L. L. Effect of arterial baroreceptor denervation on sodium balance. Hypertension 40, 547-551 (2002).
25. Sakai, R. R., McEwen, B. S., Fluharty, S. J. & Ma, L. Y. The amygdala: site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int. 57, 1337-1345 (2000).
26. +] precede the increases in blood pressure in Dahl S rats and SHR on a highsalt diet. Am. J. Physiol. Heart Circ. Physiol. 287, H1160-H2116 (2004).
27. Huang, B. S., Amin, M. S. & Leenen, F. H. The central role of the brain in salt-sensitive hypertension. Curr. Opin. Cardiol. 21, 295-304 (2006).
28. Huang, B. S. et al. Activation of brain reninangiotensin-aldosterone system by central sodium in Wistar rats. Am. J. Physiol. Heart Circ. Physiol. 291, H1109-H1117 (2006).
29. O'Donaughy, T. L., Qi, Y. & Brooks, V. L. Central action of increased osmolality to support blood pressure in deoxycorticosterone acetate-salt rats. Hypertension 48, 658-663 (2006). (Pubitemid 44843869)
30. Huang, B. S., Zheng, H., Patel, K. P. & Leenen, F. H. Central infusion of aldosterone decreases nNOS and increases AT1R and components of NADPH oxidase within the PVN [abstract PO15]. Hypertension 52, e59 (2008).
31. Zhang, Z. H., Yu, Y., Kang, Y. M., Wei, S. G. & Felder, R. B. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am. J. Physiol. Heart Circ. Physiol. 294, H1067-H1074 (2008). (Pubitemid 351253321)
32. Yu, Y. et al. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension 51, 727-733 (2008). (Pubitemid 351301527)
33. Wescott, K. V., Huang, B. S. & Leenen, F. H. Brain renin-angiotensin-aldosterone system and ventricular remodeling after myocardial infarct: a review. Can. J. Physiol. Pharmacol. 87, 979-988 (2009).
34. Felder, R. B. Mineralocorticoid receptors, inflammation and sympathetic drive in a rat model of systolic heart failure. Exp. Physiol. 95, 19-25 (2010).
35. Shi, P., Raizada, M. K. & Sumners, C. Brain cytokines as neuromodulators in cardiovascular control. Clin. Exp. Pharmacol. Physiol. 37, e52-e57 (2010).
36. Dunn, A. J. Cytokine activation of the HPA axis. Ann. NY Acad. Sci. 917, 608-617 (2000).
37. Francis, J., Weiss, R. M., Johnson, A. K. & Felder, R. B. Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R328-R335 (2003). (Pubitemid 36120147)
38. Francis, J., Beltz, T., Johnson, A. K. & Felder, R. B. Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-alpha in normal rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R1402-R1409 (2003). (Pubitemid 37464399)
39. Lastra, G., Manrique, C., McFarlane, S. I. & Sowers, J. R. Cardiometabolic syndrome and chronic kidney disease. Curr. Diab. Rep. 6, 207-212 (2006). (Pubitemid 43918646)
40. Modan, M. et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J. Clin. Invest. 75, 809-817 (1985). (Pubitemid 15111002)
41. Després, J. P. et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 334, 952-958 (1996).
42. Spät, A. & Hunyady, L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol. Rev. 84, 489-539 (2004). (Pubitemid 38365491)
43. Brilla, C. G. & Weber, K. T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 120, 893-901 (1992).
44. Stas, S. et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 148, 3773-3780 (2007). (Pubitemid 47105865)
45. Lastra, G. et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG (mRen2) 27 rat. Am. J. Physiol. Endocrinol. Metab. 295, E110-E116 (2008).
46. Endemann, D. H., Touyz, R. M., Iglarz, M., Savoia, C. & Schiffrin, E. L. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43, 1252-1257 (2004). (Pubitemid 38691747)
47. Bochud, M. et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48, 239-245 (2006). (Pubitemid 44309818)
48. Verhave, J. C. et al. for the PREVEND Study Group. Sodium intake affects urinary albumin excretion especially in overweight subjects. J. Intern. Med. 256, 324-330 (2004).
49. Fujita, T. Mineralocorticoid receptors, saltsensitive hypertension, and metabolic syndrome. Hypertension 55, 813-818 (2010).
50. Montezano, A. C. & Touyz, R. M. Networking between systemic angiotensin II and cardiac mineralocorticoid receptors. Hypertension 52, 1016-1018 (2008).
51. Yamamuro, M. et al. Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. Circ. J. 72, 1346-1350 (2008).
52. Zhang, A. D. et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 52, 1060-1067 (2008).
53. Lastra, G., Manrique, C. M. & Sowers, J. R. Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv. Chronic Kidney Dis. 13, 365-373 (2006). (Pubitemid 44512240)
54. Rossi, G. P. et al. for the Primary Aldosteronism Prevalence in hypertension Study Investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J. Clin. Endocrinol. Metab. 93, 2566-2571 (2008).
55. Jeon, J. H. et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 22, 1502-1511 (2008).
56. Caprio, M. et al. Pivotal role of the mineralocorticoid receptor in corticosteroidinduced adipogenesis. FASEB J. 21, 2185-2194 (2007). (Pubitemid 47026453)
57. Wang, H. et al. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J. Hypertension 26, 1453-1462 (2008).
58. Kawarazaki, H. et al. Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats. Nephrol. Dial. Transplant. doi:10.1093/ndt/gfql97.
59. Nagase, M., Matsui, H., Shibata, S., Gotoda, T. & Fujita, T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 50, 877-883 (2007). (Pubitemid 350287529)
60. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D. & Alexander, R. W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141-1148 (1994). (Pubitemid 24176909)
61. Copper, S. A. et al. Renin-angiotensinaldosterone system and oxidative stress in cardiovascular insulin resistance. Am. J. Physiol. Heart Circ. Physiol. 293, H2009-H2023 (2007). (Pubitemid 47605846)
62. Henquin, J. C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49, 1751-1760 (2000).
63. Shimamoto, K. et al. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J. Hum. Hypertens. 8, 755-759 (1994). (Pubitemid 24319387)
64. Brown, N. J. Aldosterone and vascular inflammation. Hypertension 51, 161-167 (2008).
65. Manrique, C., Lastra, G., Whaley-Connel, A. & Sowers, J. R. Hypertension and the cardiometabolic syndrome. J. Clin. Hypertens. (Greenwich) 7, 471-476 (2005).
66. Yusuf, S. et al. for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
67. Hansson, L. et al. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353, 611-616 (1999). (Pubitemid 29087980)
68. Pfeffer, M. A. et al. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759-766 (2003).
69. Barzilay, J. I. et al. for the ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of hypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 166, 2191-2201 (2006).
70. Shindler, D. M. et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am. J. Cardiol. 77, 1017-1020 (1996).
71. Devereux, R. B. et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110, 1456-1462 (2004). (Pubitemid 39238023)
72. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717 (1999).
73. Pitt, B. et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003).
74. Bosch, J. et al. for the DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355, 1551-1562 (2006).
75. Sowers, J. R., Whaley-Connell, A. & Epstein, M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann. Intern. Med. 150, 776-783 (2009).
76. McMurray, J. J. et al. for the NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362, 1477-1490 (2010).